Key Takeaways Tempus AI gained FDA clearance for its RNA sequencing-based xR IVD device. TEM's xR IVD detects gene rearrangements in tumor tissues from solid malignancies.The device bolsters Tempus AI's role in oncology research and drug development. RNA sequencing provides a comprehensive view of biological information, offering deeper insights into disease mechanisms, including improved fusion detection. As a powerful tool in research and development, RNA analysis helps identify molecular pathways and ne ...

ANALYSIS: Weight-Loss Craze Boosts This $186 Billion IndustryTempus AI (TEM) stock surged to a record-high Monday after the Food and Drug Administration cleared its new device to help drugmakers analyze RNA.RNA analysis is helpful in determining the mechanisms of diseases and finding molecular pathways to target specific conditions."We have long known that RNA sequencing offers additional insights beyond DNA alone, but only now are we beginning to unlock is full value in supporting therapeutic development," ...